

----- PRESS RELEASE -----

Herpen, The Netherlands, January 31, 2024

Life Sciences company Orexa raises investments of € 870,000

HERPEN, THE NETHERLANDS - Orexa B.V., a Dutch life sciences company that is developing a new medicine that increases food intake and supports health in patients, has completed a financing round of € 870,000. The investments, coming from both new as well as existing investors, will be used to further fund two phase 2 clinical trials. The first study, where the first patient has been dosed, is in the prevention of postoperative ileus and the second is a phase 2 study in patients with anorexia nervosa.

To investigate the efficacy of Orexa's lead compound ORE-001, Orexa intends to conduct three phase 2 clinical trials in different indications. The first study, in the prevention of postoperative ileus, investigates whether patients who have undergone major abdominal surgery will develop less gastrointestinal disturbances and will recover more quickly. The first of a total of 100 to 120 patients for this study has been dosed on January 11, 2024. The second phase 2 clinical trial will take place in anorexia patients, with the dosing of the first patient foreseen in Q2-'24. Finally, a third phase 2 study is being prepared aimed at people with malnutrition (sarcopenia/cachexia).

"Now that the patients in our first phase 2 clinical trial are being treated, and the treatment of patients in our second phase 2 clinical trial is expected to follow next quarter, our clinical program is clearly starting to take shape," says Prof. Dr. Ard Peeters. "We are now in the most exciting phase of the development of a new drug. By conducting these studies, we will find out whether the mechanism of action works in patients and which patient groups could benefit most."

"Thanks to both new and existing investors, we have been able to lay a solid foundation for the execution of our clinical program," according to CEO Sake Stevenhaagen. "Together with three previous funding rounds, Orexa has received a total of € 3.3 million in investments in the past 2 years. This puts us in a good position for further developments."

About Orexa:

Orexa is developing a drug that increases food intake. The markets where increased food intake can lead to substantial health benefits are large. Orexa focuses primarily on the recovery of patients who have undergone surgery, anorexia patients and elderly people with malnutrition (sarcopenia). The company is founded in 2016 and is based in Herpen (North Brabant), The Netherlands. For more information, see www.orexa.eu.